Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)
- PMID: 37595560
- DOI: 10.1016/j.cell.2023.07.031
Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)
Abstract
The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
Copyright © 2023 Elsevier Inc. All rights reserved.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical